pte20240827019 Research/Development, Medicine/Wellness
According to researchers, a single dose provides comprehensive and long-term protection and is long-lasting
Southport (pte019/27.08.2024/10:30)
A next-generation mucosal vaccine against COVID-19 is expected to be a game changer not only in the administration of the vaccine itself, but also for people who suffer from needle phobia. Researchers at the Institute for Biomedicine and Glycomics der Griffith University have tested the effectiveness of administration via the nasal passage. Details can be found in “Nature Communications”.
“CDO-7N-1” highly effective
According to research director Suresh Mahalingam, the vaccine is the attenuated intranasal vaccine “CDO-7N-1”. Because it is administered via the nose, potential mucosal immunity and systemic immunity are achieved with just a single dose. “The vaccine triggers strong immune memory responses in the mucous membrane of the nose and subsequently offers long-term protection that can last up to a year or even longer,” it says.
According to Mahalingam, who has been developing the vaccine for the past four years, it is designed to be administered in a single dose – ideally as a booster shot and as a safe alternative to administering a needle-based vaccine. According to the expert, there are no unwanted side effects in the short or long term. Attenuated live vaccines offer several advantages compared to other approaches.
According to the expert, they trigger strong and long-lasting humoral and cellular immunity. This effect can often be achieved with just one dose. Such vaccines cover the entire virus and thus enable broad immunity, in contrast to the often used individual antigens.
Shelf life at four degrees Celsius
According to research member Xiang Liu, the vaccine has cross-protection against all possible variants. In addition, CDO-7N-1 is said to have a neutralizing capacity for SARS-CoV-1. “This vaccine offers strong protection against transmission, prevents reinfection and spread of the virus, and reduces the emergence of new variants. CDO-7N-1 triggers immunity to all major SARS-CoV-2 proteins and is highly effective against all currently important variants.”
What is important, says the researcher, is that the vaccine remains stable for seven months at four degrees Celsius. This makes it ideal for use in low- and middle-income countries. The vaccine has already been tested for the major vaccine manufacturer Indian Immunologicals licensed. According to Anand Kumar, co-author and CEO of the company, all necessary tests of the new vaccine have been completed and clinical trials are already being prepared.
(End)
